If you have been reading about storage and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-20. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
The main function of striated muscle tissue is to create force and contract. These contractions in cardiac muscle will pump blood throughout the body. In skeletal muscle the contractions enable breathing, movement, and posture maintenance. Contractions in cardiac muscle tissue are due to a myogenic response of the heart's pacemaker cells. These cells respond to signals from the autonomic nervous system to either increase or decrease the heart rate. Pacemaker cells have autorhythmicity. The set intervals at which they depolarize to threshold and fire action potentials is what determines the heart rate. Because of the gap junctions, the pacemaker cells transfer the depolarization to other cardiac muscle fibers, in order to contract in unison. Signals from motor neurons cause skeletal muscle fibers to depolarize and therefore release calcium ions from the sarcoplasmic reticulum. The calcium drives the movement of myosin and actin filaments. The sarcomere then shortens which causes the muscle to contract. In the skeletal muscles connected to tendons that pull on bones, the mysia fuses to the periosteum that coats the bone. Contraction of the muscle will transfer to the mysia, then the tendon and the periosteum before causing the bone to move. The mysia also may bind to an aponeurosis or to fascia.
In this pathway, PAH molecules bind to the aryl hydrocarbon receptor (AhR) and activate it as a transcription factor that increases production of the cytochrome enzymes. The activity of these enzymes may at times conversely protect against PAH toxicity, which is not yet well understood. Low molecular weight PAHs, with two to four aromatic hydrocarbon rings, are more potent as co-carcinogens during the promotional stage of cancer. In this stage, an initiated cell (a cell that has retained a carcinogenic mutation in a key gene related to cell replication) is removed from growth-suppressing signals from its neighboring cells and begins to clonally replicate. Low-molecular-weight PAHs that have bay or bay-like regions can dysregulate gap junction channels, interfering with intercellular communication, and also affect mitogen-activated protein kinases that activate transcription factors involved in cell proliferation. Closure of gap junction protein channels is a normal precursor to cell division. Excessive closure of these channels after exposure to PAHs results in removing a cell from the normal growth-regulating signals imposed by its local community of cells, thus allowing initiated cancerous cells to replicate. These PAHs do not need to be enzymatically metabolized first. Low molecular weight PAHs are prevalent in the environment, thus posing a significant risk to human health at the promotional phases of cancer.
==== September ==== The Syrian Observatory for Human Rights reported that Firas Hamayel, a commander in the National Guard, was killed in an ambush in Suwayda. On 21 September, Ayoob Kara, former member of the Israeli Knesset, announced the independence of Suwayda, declaring "We proclaim September 21, 2025, as the historic day of Suwayda’s separation from Syria and from the terrorist government of Ahmed Al-Sharaa". On 26 September, the Syrian Druze militias established a local women's self-defense army as a response to the precarious security situation. More than 500 women are involved. Minors have been forcibly trained to use weapons. On 27 September, the Syrian transitional government bombed the city of Mecdel with a drone and also bombed the city of Kanaker.
Sources: en.wikipedia.org
Dihydromorphine (Paramorfan, Paramorphan) is a semi-synthetic opioid structurally related to and derived from morphine. The 7,8-double bond in morphine is reduced to a single bond to get dihydromorphine. Dihydromorphine is a moderately strong analgesic and is used clinically in the treatment of pain and also is an active metabolite of the analgesic opioid drug dihydrocodeine. Dihydromorphine occurs in trace quantities in assays of opium on occasion, as does dihydrocodeine, dihydrothebaine, tetrahydrothebaine, etc. The process for manufacturing dihydromorphine from morphine for pharmaceutical use was developed in Germany in the late 19th century, with the synthesis being published in 1900 and the drug introduced clinically as Paramorfan shortly thereafter. A high-yield synthesis from tetrahydrothebaine was later developed.
== List of anorectics == Numerous pharmaceutical compounds are marketed as appetite suppressants. The following drugs are listed as "centrally-acting antiobesity preparations" in the Anatomical Therapeutic Chemical Classification System:
This work hinged on his demonstration that red blood cell glutathione was unstable to oxidative stress. Later, he was to develop an assay for glutathione that was widely used in studies of red cell oxidative metabolism. He was later transferred to Camp Detrick in Frederick, Maryland (1954–1955), where he studied Q fever. He was honorably discharged from the Army with the rank of captain. Beutler then joined the faculty of the Department of Medicine at the University of Chicago, where he studied iron metabolism and red blood cell metabolism. In 1959, he became chairman of the Department of Medicine of the City of Hope National Medical Center in Duarte, California, and in 1979 assumed the chairmanship of the Department of Clinical Research at the Scripps Clinic and Research Foundation. Three years later, he was asked to become Chairman of a merged department (the Department of Molecular and Experimental Medicine) at Scripps, which later became The Scripps Research Institute in La Jolla, CA. He maintained his position as Chairman until his 80th birthday, only a few days before his death. Not long after moving to California, Beutler made one of his most important contributions. A new colleague at the City of Hope and ultimately a lifelong friend, Susumu Ohno had recently demonstrated that the histologically observable Barr body present in the nuclei of mammalian female cells was a hyperchromatic X chromosome. Beutler immediately recognized that this might account for the variable expression of X-linked genes in females heterozygous for X-linked mutations.
In chemistry, a hydrogen bond (H-bond) is a specific type of molecular interaction that exhibits partial covalent character and cannot be described as a purely electrostatic force. It occurs when a hydrogen (H) atom, covalently bonded to a more electronegative donor atom or group (Dn), interacts with another electronegative atom bearing a lone pair of electrons—the hydrogen bond acceptor (Ac). Unlike simple dipole–dipole interactions, hydrogen bonding arises from charge transfer (nB → σ*AH), orbital interactions, and quantum mechanical delocalization, making it a resonance-assisted interaction rather than a mere electrostatic attraction. The general notation for hydrogen bonding is Dn−H···Ac, where the solid line represents a polar covalent bond, and the three dots indicate the hydrogen bond. Hydrogen bond donors have a protic hydrogen attached to an electronegative atom such as nitrogen (N), oxygen (O), and fluorine (F). Hydrogen bond acceptors have a lone pair of electrons, such as the nitrogen atom of amines and amides and the oxygen atom of carboxylates and water. The term "hydrogen bond" is generally used for well-defined, localized interactions with significant charge transfer and orbital overlap, such as those in DNA base pairing or ice. In contrast, "hydrogen-bonding interactions" is a broader term used when the interaction is weaker, more dynamic, or delocalized, such as in liquid water, supramolecular assemblies (e.g.: lipid membranes, protein-protein interactions), or weak C-H···O interactions.
Sources: en.wikipedia.org
=== United Kingdom === Beef Stroganoff began appearing in British cookery books in the early 1930s and became widely popular by the 1970s, particularly in restaurants and at dinner parties. The dish later declined in popularity and became associated with mass-produced ready meals and buffet-style catering. Modern British adaptations often include a creamy sauce made with white wine or brandy, sour cream or crème fraîche, and additions such as smoked paprika and English mustard. While beef fillet was traditionally used, contemporary recipes frequently use alternative proteins such as pork, chicken or sausages. The dish is commonly served with rice, tagliatelle, or potatoes. In recent years, it has experienced limited revival in British food media, pub cuisine, and home cooking.
=== Protein-RNA interaction network identification === Protein-RNA interactions networks are identified using RNP-MaP correlations since multiple crosslink sites can be detected for a single RNA molecule. RNP-MaP correlations provide a complementary measure of protein binding to RNA independent of RNP-MaP sites. They are identified using a G-test framework known as RingMapper. RNP-MaP correlations require a single RNA molecule to form at least two crosslinks and arise from any of three scenarios:
== Electrochemical Carbon nanotube filter == Carbon nanotubes have gained much attention for its use as wastewater and water filter. Carbon nanotube’s mechanical, electrical and chemical properties made it unique and an ideal candidate for research since 1990. Carbon nanotube combined with electrochemistry proved to be the best method for water and wastewater purification. Electrochemistry helps in reducing the fouling rate of the CNT. In case of CNT based ultra-filters modified with electrochemistry, helps in reducing the energy by two folds comparing to an unmodified CNT based filters. Thus electrochemical carbon nanotubes have been developed due to the advanced studies in nanotechnology and electrochemistry. Here the electrochemical activity of the CNT is exploited. Very first electrochemical CNT was developed by P.J.Britto etal and the results were first recognized in 1996. An electrochemical CNT filter contains electrodes and CNT in a systematic setup such that the electrodes can attract the wastes that clog the CNT based on its charges, thus resulting in high efficiency of filtering and extension of the lifetime of the CNT in the process. The electrochemical carbon nanotubes can be easily used for removing amino group based dyes from wastewater. Chen etal first reported the absorption of dyes to the CNT walls by strong covalent bonds. These electrochemical CNT can be typically used for filtering, and recycling wastewater.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.